174 related articles for article (PubMed ID: 26334953)
21. Stick-Based Methods for Aptamer-Mediated siRNA Targeted Delivery.
Catuogno S; Esposito CL; Giangrande PH
Methods Mol Biol; 2021; 2282():31-42. PubMed ID: 33928568
[TBL] [Abstract][Full Text] [Related]
22. An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing αvβ3 integrin.
Hussain AF; Tur MK; Barth S
Nucleic Acid Ther; 2013 Jun; 23(3):203-12. PubMed ID: 23544955
[TBL] [Abstract][Full Text] [Related]
23. Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition.
Edwards SL; Poongavanam V; Kanwar JR; Roy K; Hillman KM; Prasad N; Leth-Larsen R; Petersen M; Marušič M; Plavec J; Wengel J; Veedu RN
Chem Commun (Camb); 2015 Jun; 51(46):9499-502. PubMed ID: 25968110
[TBL] [Abstract][Full Text] [Related]
24. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
25. LNA-antisense rivals siRNA for gene silencing.
Jepsen JS; Wengel J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
[TBL] [Abstract][Full Text] [Related]
26. LNA derivatives of a kissing aptamer targeted to the trans-activating responsive RNA element of HIV-1.
Lebars I; Richard T; Di Primo C; Toulmé JJ
Blood Cells Mol Dis; 2007; 38(3):204-9. PubMed ID: 17300966
[TBL] [Abstract][Full Text] [Related]
27. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality.
Elmén J; Thonberg H; Ljungberg K; Frieden M; Westergaard M; Xu Y; Wahren B; Liang Z; Ørum H; Koch T; Wahlestedt C
Nucleic Acids Res; 2005; 33(1):439-47. PubMed ID: 15653644
[TBL] [Abstract][Full Text] [Related]
28. Aptamer-siRNA chimeras: Promising tools for targeting HER2 signaling in cancer.
Dhanya CR; Mary AS; Madhavan M
Chem Biol Drug Des; 2023 May; 101(5):1162-1180. PubMed ID: 36099164
[TBL] [Abstract][Full Text] [Related]
29. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2.
Wullner U; Neef I; Eller A; Kleines M; Tur MK; Barth S
Curr Cancer Drug Targets; 2008 Nov; 8(7):554-65. PubMed ID: 18991566
[TBL] [Abstract][Full Text] [Related]
30. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras.
Lai WY; Wang WY; Chang YC; Chang CJ; Yang PC; Peck K
Biomaterials; 2014 Mar; 35(9):2905-14. PubMed ID: 24397988
[TBL] [Abstract][Full Text] [Related]
31. DNA Polymerase Variants with High Processivity and Accuracy for Encoding and Decoding Locked Nucleic Acid Sequences.
Hoshino H; Kasahara Y; Kuwahara M; Obika S
J Am Chem Soc; 2020 Dec; 142(51):21530-21537. PubMed ID: 33306372
[TBL] [Abstract][Full Text] [Related]
32. Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system.
Wei J; Song R; Sabbagh A; Marisetty A; Shukla N; Fang D; Najem H; Ott M; Long J; Zhai L; Lesniak MS; James CD; Platanias L; Curran M; Heimberger AB
Oncoimmunology; 2022; 11(1):2062827. PubMed ID: 35433114
[TBL] [Abstract][Full Text] [Related]
33. Blocking the maturation of OncomiRNAs using pri-miRNA-17∼92 aptamer in retinoblastoma.
Subramanian N; Kanwar JR; Kanwar RK; Krishnakumar S
Nucleic Acid Ther; 2015 Feb; 25(1):47-52. PubMed ID: 25513843
[TBL] [Abstract][Full Text] [Related]
34. Current progress on aptamer-targeted oligonucleotide therapeutics.
Dassie JP; Giangrande PH
Ther Deliv; 2013 Dec; 4(12):1527-46. PubMed ID: 24304250
[TBL] [Abstract][Full Text] [Related]
35. Aptamer-Mediated Delivery and Cell-Targeting Aptamers: Room for Improvement.
Yan AC; Levy M
Nucleic Acid Ther; 2018 Jun; 28(3):194-199. PubMed ID: 29883295
[TBL] [Abstract][Full Text] [Related]
36. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
Li X; Zhao Q; Qiu L
J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
[TBL] [Abstract][Full Text] [Related]
37. The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence.
Fluiter K; Mook OR; Baas F
Methods Mol Biol; 2009; 487():189-203. PubMed ID: 19301648
[TBL] [Abstract][Full Text] [Related]
38. Properties of an LNA-modified ricin RNA aptamer.
Förster C; Zydek M; Rothkegel M; Wu Z; Gallin C; Geßner R; Lisdat F; Fürste JP
Biochem Biophys Res Commun; 2012 Mar; 419(1):60-5. PubMed ID: 22326915
[TBL] [Abstract][Full Text] [Related]
39. In silico designed RNA aptamer against epithelial cell adhesion molecule for cancer cell imaging.
Bavi R; Liu Z; Han Z; Zhang H; Gu Y
Biochem Biophys Res Commun; 2019 Feb; 509(4):937-942. PubMed ID: 30648555
[TBL] [Abstract][Full Text] [Related]
40. Locked nucleic acid aptamers.
Barciszewski J; Medgaard M; Koch T; Kurreck J; Erdmann VA
Methods Mol Biol; 2009; 535():165-86. PubMed ID: 19377996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
